A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pheast Therapeutics
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
Toray Industries, Inc
National Cancer Institute (NCI)
Eli Lilly and Company
Kyowa Kirin Co., Ltd.
City of Hope Medical Center
AstraZeneca
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Altor BioScience
Dartmouth-Hitchcock Medical Center
GOG Foundation
National Cancer Institute (NCI)
GOG Foundation
Astellas Pharma Inc
Memorial Sloan Kettering Cancer Center